Clinical Trial Update: MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the AKT inhibitor MK-2206 in combination with Paclitaxel for locally advanced or metastatic solid tumors and metastatic breast cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• MK-2206 (MK-2206)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Recurrent Breast Carcinoma | Phase 1 | Status: COMPLETED